Payment overview · 2025
General Payments
$1,683.44
98 reported records · 22 companies
Healthcare provider profile · identity verified
Teigha Jan Randolph, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KINSTON, NC · NPI 1811972425
Verified facts
What the public records show
CMS Open Payments records show Teigha Jan Randolph, MD received $1,683.44 in general payments during 2025 across 98 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 674 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 674 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $314.70 | 18.7% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $249.73 | 14.8% | 21 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $229.84 | 13.7% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $194.93 | 11.6% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.18 | 11.4% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.02 | 3.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.13 | 3.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.44 | 3.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.73 | 2.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.07 | 2.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $29.80 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.14 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.16 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.36 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.42 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.31 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.67 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.80 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.49 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.87 | 0.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.39 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.26 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,683.44 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $261.24 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $229.84 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $216.56 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $192.25 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $180.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.26 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.26 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $116.47 | 10 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $108.06 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.62 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.62 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.02 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.13 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.13 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.24 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.73 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $40.07 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.59 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $2.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 674 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 284 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 388 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 196 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 300 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
196 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
143 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
284 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
103 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
388 | 67 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
674 | 145 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
388 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
300 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
674 | 145 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1854 | 397 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1636 | 364 |
| Omeprazole | Omeprazole | 1602 | 353 |
| Potassium Chloride | Potassium Chloride | 1535 | 314 |
| Metoprolol Succinate | Metoprolol Succinate | 1336 | 271 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1133 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1131 | 189 |
| Furosemide | Furosemide | 912 | 230 |
| Gabapentin | Gabapentin | 823 | 199 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 810 | 158 |
| Metformin Hcl | Metformin Hcl | 768 | 168 |
| Eliquis | Apixaban | 674 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 669 | 154 |
| Hydrochlorothiazide | Hydrochlorothiazide | 632 | 151 |
| Losartan Potassium | Losartan Potassium | 631 | 145 |
| Simvastatin | Simvastatin | 603 | 120 |
| Lisinopril | Lisinopril | 546 | 116 |
| Sertraline Hcl | Sertraline Hcl | 528 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 490 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 444 | 163 |
| Tamsulosin Hcl | Tamsulosin Hcl | 439 | 91 |
| Tramadol Hcl | Tramadol Hcl | 423 | 109 |
| Jardiance | Empagliflozin | 388 | 67 |
| Valsartan | Valsartan | 379 | 81 |
| Meloxicam | Meloxicam | 372 | 101 |
| Glimepiride | Glimepiride | 366 | 77 |
| Carvedilol | Carvedilol | 355 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 343 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 340 | 68 |
| Cefuroxime | Cefuroxime Axetil | 336 | 262 |
| Fluoxetine Hcl | Fluoxetine Hcl | 322 | 65 |
| Allopurinol | Allopurinol | 301 | 64 |
| Ozempic | Semaglutide | 300 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 287 | 95 |
| Farxiga | Dapagliflozin Propanediol | 284 | 55 |
| Alprazolam | Alprazolam | 279 | 69 |
| Atenolol | Atenolol | 276 | 51 |
| Benazepril Hcl | Benazepril Hcl | 276 | 52 |
| Trazodone Hcl | Trazodone Hcl | 261 | 69 |
| Prednisone | Prednisone | 253 | 181 |
| Fluticasone Propionate | Fluticasone Propionate | 249 | 76 |
| Temazepam | Temazepam | 231 | 44 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 228 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 223 | 45 |
| Finasteride | Finasteride | 220 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 214 | 46 |
| Levetiracetam | Levetiracetam | 213 | 39 |
| Xarelto | Rivaroxaban | 209 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 205 | 42 |
| Clonazepam | Clonazepam | 199 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 198 | 58 |
| Linzess | Linaclotide | 196 | 36 |
| Glipizide | Glipizide | 191 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 186 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 183 | 45 |
| Spironolactone | Spironolactone | 181 | 54 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 180 | 42 |
| Torsemide | Torsemide | 176 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 175 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 174 | 40 |
| Montelukast Sodium | Montelukast Sodium | 172 | 38 |
| Meclizine Hcl | Meclizine Hcl | 165 | 53 |
| Donepezil Hcl | Donepezil Hcl | 163 | 37 |
| Estradiol | Estradiol | 163 | 39 |
| Telmisartan | Telmisartan | 160 | 35 |
| Nifedipine Er | Nifedipine | 158 | 28 |
| Warfarin Sodium | Warfarin Sodium | 158 | 23 |
| Famotidine | Famotidine | 157 | 40 |
| Lorazepam | Lorazepam | 157 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 40 |
| Pregabalin | Pregabalin | 156 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 32 |
| Synthroid | Levothyroxine Sodium | 143 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 143 | 34 |
| Colchicine | Colchicine | 141 | 36 |
| Clonidine Hcl | Clonidine Hcl | 137 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 26 |
| Ezetimibe | Ezetimibe | 118 | 26 |
| Entresto | Sacubitril/Valsartan | 117 | 25 |
| Ondansetron Odt | Ondansetron | 114 | 25 |
| Irbesartan | Irbesartan | 112 | 23 |
| Divalproex Sodium | Divalproex Sodium | 111 | 16 |
| Metformin Hcl Er | Metformin Hcl | 110 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 105 | 20 |
| Celecoxib | Celecoxib | 103 | 44 |
| Symbicort | Budesonide/Formoterol Fumarate | 103 | 27 |
| Alendronate Sodium | Alendronate Sodium | 102 | 26 |
| Mirtazapine | Mirtazapine | 102 | 36 |
| Levofloxacin | Levofloxacin | 100 | 83 |
| Lactulose | Lactulose | 99 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 97 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 64 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 95 | 78 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 20 |
| Indapamide | Indapamide | 90 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 16 |
| Mounjaro | Tirzepatide | 87 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 22 |
| Gemfibrozil | Gemfibrozil | 86 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 34 |
| Nystatin | Nystatin | 83 | 43 |
| Metoclopramide Hcl | Metoclopramide Hcl | 80 | 18 |
| Glipizide Er | Glipizide | 79 | 18 |
| Myrbetriq | Mirabegron | 79 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 78 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 19 |
| Hydrocortisone | Hydrocortisone | 74 | 46 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 34 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 69 | 15 |
| Cephalexin | Cephalexin | 69 | 48 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 67 | 14 |
| Verapamil Er | Verapamil Hcl | 66 | 12 |
| Propranolol Hcl | Propranolol Hcl | 65 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 64 | 17 |
| Topiramate | Topiramate | 63 | 13 |
| Bupropion Xl | Bupropion Hcl | 62 | 16 |
| Glyburide | Glyburide | 62 | 12 |
| Lansoprazole | Lansoprazole | 61 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 11 |
| Clonidine | Clonidine | 59 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Risperidone | Risperidone | 57 | suppressed |
| Klor-Con M20 | Potassium Chloride | 56 | 23 |
| Lovastatin | Lovastatin | 56 | 15 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 55 | 11 |
| Sucralfate | Sucralfate | 55 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Fluconazole | Fluconazole | 53 | 36 |
| Calcitriol | Calcitriol | 52 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 12 |
| Lacosamide | Lacosamide | 49 | suppressed |
| Lamotrigine | Lamotrigine | 49 | suppressed |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 46 |
| Baclofen | Baclofen | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | 14 |
| Ibuprofen | Ibuprofen | 45 | 17 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 45 | 32 |
| Naproxen | Naproxen | 45 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Gemtesa | Vibegron | 44 | 11 |
| Carbamazepine | Carbamazepine | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 24 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 22 |
| Chlorthalidone | Chlorthalidone | 39 | 15 |
| Enalapril Maleate | Enalapril Maleate | 39 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 28 |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | 15 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | 19 |
| Promethazine Hcl | Promethazine Hcl | 36 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 31 |
| Ramipril | Ramipril | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Nystop | Nystatin | 34 | 25 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Auryxia | Ferric Citrate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Digoxin | Digoxin | 27 | suppressed |
| Minoxidil | Minoxidil | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 11 |
| Mitigare | Colchicine | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 22 |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 19 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 17 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Mesalamine Er | Mesalamine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,683.44 · 98 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, AUSTEDO XR, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VIBERZI, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error